Physician profile
Nejra Tabakovic
NPI 1376281949
$10,662.69
in general payments reported to CMS, 2019-2025
60 companies · $3,692 in 2025
The $3,692 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $443 · 2023: $2,889 · 2024: $3,638 · 2025: $3,692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,003.53 |
| Education | $215.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,066.44 | 2023-2025 | Enhertu, Datroway |
| Novartis Pharmaceuticals Corporation | $1,027.78 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $829.90 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Incyte Corporation | $713.20 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Astrazeneca Pharmaceuticals Lp | $634.40 | 2023-2025 | Enhertu, Imfinzi, Lynparza |
| Janssen Biotech, INC. | $544.33 | 2022-2025 | Rybrevant, Darzalex, Carvykti |
| Gilead Sciences, INC. | $493.27 | 2022-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $326.79 | 2022-2025 | Libtayo |
| Pfizer INC. | $282.87 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $270.30 | 2023-2024 | Rezlidhia, Tavalisse |
| Sobi, INC | $242.97 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $214.60 | 2024-2025 | Monoferric, Cosela |
| Seagen INC. | $206.81 | 2022-2023 | Padcev, Tukysa, Adcetris |
| Takeda Pharmaceuticals U.S.A., INC. | $203.33 | 2023-2025 | Fruzaqla, Iclusig, Alunbrig |
| Lilly USA, LLC | $202.04 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $189.62 | 2023-2025 | |
| Adaptive Biotechnologies Corporation | $173.32 | 2024-2025 | Clonoseq |
| Array Biopharma INC | $171.71 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Glaxosmithkline, LLC. | $160.33 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Csl Behring | $157.01 | 2023-2025 | Idelvion, Afstyla |
| Eisai INC. | $156.53 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.09 | 2022-2025 | |
| Foundation Medicine, INC. | $140.97 | 2023 | |
| Genentech USA, INC. | $134.54 | 2022-2025 | Phesgo, Perjeta, Kadcyla |
| Abbvie INC. | $131.17 | 2024-2025 | |
| Astellas Pharma Global Development | $125.45 | 2023 | Padcev |
| Taiho Oncology, INC. | $124.15 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $122.34 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $100.48 | 2025 | Onivyde |
| E.R. Squibb & Sons, L.L.C. | $100.25 | 2024-2025 | Opdivo, Opdualag |
| Cti Biopharma Corp. | $93.78 | 2022-2023 | Vonjo |
| Beigene USA, INC. | $92.45 | 2024-2025 | Tevimbra |
| Aveo Pharmaceuticals, INC. | $77.46 | 2022-2024 | Fotivda |
| Emd Serono, INC. | $74.01 | 2024-2025 | |
| Tersera Therapeutics LLC | $71.12 | 2023-2025 | Zoladex |
| Alexion Pharmaceuticals, INC. | $71.01 | 2024 | Ultomiris |
| Karyopharm Therapeutics INC. | $62.38 | 2022-2024 | Xpovio |
| Agios Pharmaceuticals, INC. | $54.17 | 2022-2024 | Pyrukynd |
| Pharmaessentia USA Corporation | $53.81 | 2025 | Besremi |
| Stemline Therapeutics INC. | $53.26 | 2023-2024 | Orserdu |
| Sun Pharmaceutical Industries INC. | $49.35 | 2022-2025 | Yonsa, Odomzo |
| Adc Therapeutics America, INC. | $46.98 | 2023-2024 | |
| Kyowa Kirin, INC. | $45.96 | 2023-2025 | Poteligeo |
| Sumitomo Pharma America, INC. | $45.52 | 2024-2025 | Orgovyx |
| Morphosys, US INC. | $45.29 | 2023 | Monjuvi |
| Puma Biotechnology, INC. | $38.63 | 2023 | |
| Genmab U.S., INC. | $34.06 | 2023 | Epkinly |
| Beone Medicines USA, INC. | $27.30 | 2025 | Tevimbra |
| Alnylam Pharmaceuticals INC. | $23.24 | 2023 | Givlaari |
| Progenics Pharmaceuticals, INC. | $22.74 | 2023 | Pylarify |
| Geron Corporation | $22.37 | 2025 | Rytelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.35 | 2024 | Gilotrif |
| Mirati Therapeutics, INC. | $21.08 | 2023 | Krazati |
| Amgen INC. | $20.65 | 2023 | Lumakras |
| Myriad Genetic Laboratories, INC. | $19.19 | 2024 | Myrisk |
| Astellas Pharma US INC | $18.84 | 2023 | Xospata |
| Servier Pharmaceuticals LLC | $18.49 | 2024 | |
| Janssen Pharmaceuticals, INC | $16.07 | 2023 | Xarelto |
| Verity Pharmaceuticals INC. | $14.96 | 2023 | Trelstar |
| Novocure INC. | $14.18 | 2025 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nejra Tabakovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.